We are pleased to announce that as of October 1, 2018, Aetna — a Fortune 500 Company that has been described by the New York Times as “one of the most progressive actors in corporate America” — has accepted Acutis as a national, in-network provider.
Acutis maintains its commitment to its clients and the industry with:
A no-compromise work ethic that adheres to protocols that have no tolerance for error.
Our proprietary 728 Patient Report™ that enables clinical decisions by pointing out abuse of prescription/illicit drugs that are too often missed by providers.
A sense of urgency — 97% of our reports are delivered by the next business day.
A payor-centric approach that believes good healthcare delivered at the lowest cost is a business imperative.
An adherence to “medical necessity” as the only basis for testing, which leads to better patient outcomes with minimal testing.
Only a few, select clinical toxicology laboratories have been accepted as Aetna in-network providers. We see our acceptance as an affirmation, not only for Acutis as a whole, but of every single member of our company, from our PhDs to our support staff. We are honored to have earned Aetna’s trust and will work hard and smart to keep it.
“We will continue to refine our science and technology to ensure greater accuracy and consistency, as well as regular cost savings and rapid turn-around time. What’s more, our ongoing investment in research and development will lead to greater advancements in clinical toxicology, as well as state-of-the-art diagnostic tests in infectious disease and molecular diagnostics.”
— Jibreel Sarij, Acutis’ CEO
Kommentarer